Zydus Cadila signs LoI with Microbix Biosystems for Urokinase

07 Jan 2012 Evaluate

Microbix Biosystems Inc., a biotechnology company commercializing novel technologies and Zydus Cadila , an Indian global pharmaceutical company have signed a letter of intent (LoI) to market the Thrombolytic drug, Urokinase in the North American markets.

The two companies expect a definitive agreement to be signed early in 2012, while the anticipated time-line for approval is late 2014. As per the terms of the agreement between both the companies, Zydus is required to provide the funding needed to re-launch the drug in the US and Canada, including an initial commitment, plus milestone based payments.

The estimated market size of the Urokinase use in the US alone is expected to touch $400 million by 2020 between three indications: pulmonary embolism, catheter clerarence and catheter prophylaxis.

Urokinase was acquired by Microbix in 2008 which has since then stepped up efforts to re-introduce the drug in North America.

Zydus Wellness Share Price

409.20 -6.95 (-1.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Nestle 1246.65
Varun Beverages 479.95
Britannia Inds 5961.10
LT Foods 397.00
Hatsun Agro Product 1034.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×